Pages that link to "Q5207712"
Jump to navigation
Jump to search
The following pages link to daclatasvir (Q5207712):
Displaying 50 items.
- World Health Organization Model List of Essential Medicines (Q37155) (← links)
- liver cirrhosis (Q147778) (← links)
- hepatitis C (Q154869) (← links)
- Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C (Q26745769) (← links)
- Daclatasvir: potential role in hepatitis C (Q27012741) (← links)
- Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition (Q27335920) (← links)
- daclatasvir/sofosbuvir (Q27791722) (← links)
- A Review of Daclatasvir Drug-Drug Interactions (Q28068712) (← links)
- Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis (Q28073108) (← links)
- Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection (Q28075544) (← links)
- Daklinza (Q29005694) (← links)
- Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection (Q29620338) (← links)
- NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. (Q30352718) (← links)
- Daclatasvir: A Review in Chronic Hepatitis C. (Q30392100) (← links)
- Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration (Q30685690) (← links)
- Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction (Q31151179) (← links)
- Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data (Q31170657) (← links)
- Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders (Q33420608) (← links)
- Sofosbuvir in combination with daclatasvir in liver transplant recipients with HCV infection: A systematic review and meta-analysis (Q33438356) (← links)
- Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort (Q33557819) (← links)
- Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients (Q33576524) (← links)
- Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. (Q33622970) (← links)
- The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate (Q33794371) (← links)
- Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system (Q34022926) (← links)
- Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life (Q34035703) (← links)
- Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052 (Q34185949) (← links)
- Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect (Q34416181) (← links)
- Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C (Q34536041) (← links)
- In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. (Q34634693) (← links)
- Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052 (Q34634791) (← links)
- Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor (Q34636796) (← links)
- Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. (Q34638767) (← links)
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection (Q35044909) (← links)
- Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides (Q35070501) (← links)
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study (Q35538245) (← links)
- High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms (Q35907984) (← links)
- Assessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone (Q35960681) (← links)
- Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b (Q35962458) (← links)
- An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects (Q35980958) (← links)
- No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects (Q36083734) (← links)
- Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. (Q36148043) (← links)
- The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease (Q36243096) (← links)
- Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir (Q36276803) (← links)
- Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus (Q36687938) (← links)
- Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1 (Q36724391) (← links)
- Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. (Q36785846) (← links)
- Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation (Q36816846) (← links)
- 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens (Q36948115) (← links)
- Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan (Q36970046) (← links)
- Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir (Q37057877) (← links)